Skin Side Effects of Epidermal Growth Factor Receptor Inhibitors in Oncologic Therapy
Authors:
M. Kuklová 1; S. Urbanček 1; M. Šimaljaková 2
Authors‘ workplace:
Dermatovenerologická klinika SZU, FNsP F. D. Roosevelta, Banská Bystrica
1; Dermatovenerologická klinika LFUK a FNsP, Bratislava
2
Published in:
Čes-slov Derm, 85, 2010, No. 2, p. 92-98
Category:
Pharmacologyand Therapy, Clinical Trials
Overview
In the last decade a new agents of anticancer therapy have been introduced. These agents include monoclonal antibodies, tyrosine kinase inhibitors, proteasome inhibitors and inhibitors of angiogenesis. Even though the targeted therapy is very effective it is associated with a lot of different side-effects, of which cutaneous are the most common. These are very often observed during therapy with inhibitors of epidermal growth factor and of its receptor.
Key words:
targeted therapy – monoclonal antibodies – tyrosine kinase inhibitors – epidermal growth factor receptor – side-effects
Sources
1. Deslandres, M., Sibaud, V., Chevreau, C., Delord, J.-P. Effets secondaires cutanés des nouvelles molécules anticancéreuses: focus sur les molécules ciblant les récepteurs tyrosine kinase et le récepteur á I’EGF. Ann Dermatol Venerol, hors série 1, 2008, p. 16-24.
2. Dick, SE., Crawford, GH. Managing cutaneous side effects of epidermal growth factor receptor (HER1/EGFR) inhibitors. Commun Oncol, 2005, 2, p. 492-496.
3. Iacovelli, L. Clinical management of EGFRI-associated dermatologic toxicities: Pharmacy perspective. Oncology, 2007,11(5), p.31-33.
4. Klener, P. Omezilo zavádění tzv. cílené léčby význam protinádorovej chemoterapie? Onkológia, 2007, 2(6), s. 363-366.
5. Krajsová, I. Kožní projevy cílené léčby nádorů. Remedia, 2006, 16, s.416-420
6. Lacouture, ME., Melosky, BL. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor:A dermatology-oncology perspective. Skin Therapy Letter, 2007, 12 (6), p.1-5.
7. Lee, MV., Seo, CW., Kim, SW., Yang, HJ., Lee, HW., Choi, JH., Moon, KC., Koh, JK. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol, 2004, 84 (1), p.23-26.
8. Lynch, TJ. Jr., Kim, ES., Eaby, B., Garey, J., West, DP., Lacouture, ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. The Oncologist, 2007, 12 (5), p.610-621.
9. National Cancer institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, May 28, 2009 (v4.02:Sept.15, 2009), http://evs.nei.nih.gov/ftp1/CTCAEַ4. 02ַ2009-09-15ַQuickReferenceַ5x7.pdf
10. Robert, C., Mateus, Ch., Spatz, A., Wechsler, J., Escudier, B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol, 2009, 60, p. 299-305.
11. Robert, C., Soria, J-C., Spatz, A., Le Cesne, a., Malka, D., Pautier, P., Wechsler, J., Lhomme, C., Escudier, B., Boige, V., Armand, J-P., Le Chevalier, T. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol, 2005, 6, p.491-500.
12. Rodeck, U. Skin toxicity caused by EGFR antagonists – an autoinflamatory condition triggered by deregulated IL-1 signaling? J Cell Physiol, 2009, 218 (1), p.32-34.
13. Segaert, S., Van Cutsem, E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol, 2005, 16(9), p.1425-1433.
14. Siegfried, S., Van Cutsem, E. Clinical management of EGFRI dermatologic toxicities: The European perspective. Oncology, 2007, 21(11), p. 22-26.
15. Tan, AR., Steinberg, SM., Parr, AL., Nguyen, D., Yang, SX. Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment. Ann Oncol, 2008, 19(1), p.185-190.
Labels
Dermatology & STDs Paediatric dermatology & STDsArticle was published in
Czech-Slovak Dermatology
2010 Issue 2
Most read in this issue
- A Case Study of a Female with Atypical Localization of Syphilitic Chancre
- Skin Reactions to New Agents (Biologicals and Targeted Anticancer Drugs)
- Rosacea Fulminans
- Skin Side Effects of Epidermal Growth Factor Receptor Inhibitors in Oncologic Therapy